Meeting NewsVideo

VIDEO: Significant improvements for skin disease activity seen in patients with dermatomyositis treated with anabasum

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Victoria P. Werth, MD, spoke about a study that evaluated the safety and efficacy of anabasum (JBT-101, Corbus Pharmaceuticals) in patients with dermatomyositis. She said patients treated with anabasum saw significant improvements for measures of skin disease activity.

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Victoria P. Werth, MD, spoke about a study that evaluated the safety and efficacy of anabasum (JBT-101, Corbus Pharmaceuticals) in patients with dermatomyositis. She said patients treated with anabasum saw significant improvements for measures of skin disease activity.

    See more from American College of Rheumatology Annual Meeting